Peter Blume-Jensen - 21 Feb 2025 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Role: President and CEO, Director
Signature: /s/ Rasmus Holm-Jorgensen, Attorney-in-Fact for Peter Blume-Jensen
Issuer symbol: ACRV
Transactions as of: 21 Feb 2025
Net transactions value: -$110,268
Form type: 4
Filing time: 25 Feb 2025, 16:09:41 UTC
Previous filing: 19 Feb 2025
Next filing: 04 Mar 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACRV	Common Stock	Tax liability	$110,268	-19,904	-0.86%	$5.54	2,285,781	21 Feb 2025	Direct	F1, F2
holding	ACRV	Common Stock						316,177	21 Feb 2025	See Footnote	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.
F2	These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.
F3	These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.